BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22510247)

  • 1. The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: a 4-year follow-up study.
    Kampylafka EI; Kosmidis ML; Panagiotakos DB; Dalakas M; Moutsopoulos HM; Tzioufas AG
    Clin Exp Rheumatol; 2012; 30(3):397-401. PubMed ID: 22510247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients.
    Marie I; Menard JF; Hatron PY; Hachulla E; Mouthon L; Tiev K; Ducrotte P; Cherin P
    Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1748-55. PubMed ID: 20722047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients.
    Cherin P; Pelletier S; Teixeira A; Laforet P; Genereau T; Simon A; Maisonobe T; Eymard B; Herson S
    Arthritis Rheum; 2002 Feb; 46(2):467-74. PubMed ID: 11840450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease.
    Bounfour T; Bouaziz JD; Bézier M; Cordoliani F; Saussine A; Petit A; Juillard C; Bagot M; Rybojad M
    J Eur Acad Dermatol Venereol; 2014 Sep; 28(9):1150-7. PubMed ID: 23906502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of high-dose intravenous human immunoglobulins treatment for refractory recurrent pericarditis.
    Moretti M; Buiatti A; Merlo M; Massa L; Fabris E; Pinamonti B; Sinagra G
    Am J Cardiol; 2013 Nov; 112(9):1493-8. PubMed ID: 23972350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients.
    Dobloug C; Walle-Hansen R; Gran JT; Molberg Ø
    Clin Exp Rheumatol; 2012; 30(6):838-42. PubMed ID: 22935197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus.
    Sami N; Qureshi A; Ahmed AR
    Eur J Dermatol; 2002; 12(2):174-8. PubMed ID: 11872417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis.
    Galimberti F; Kooistra L; Li Y; Chatterjee S; Fernandez AP
    Clin Exp Dermatol; 2018 Dec; 43(8):906-912. PubMed ID: 29856076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intravenous immunoglobulin treatment in autoimmune diseases].
    Danieli MG; Calcabrini L; Marchetti A; Calabrese V; Pettinari L; Massaccesi C; Gabrielli A; Danieli G
    Recenti Prog Med; 2007 Jun; 98(6):322-6. PubMed ID: 17580523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term remission of severe refractory dermatopolymyositis with a weekly-scheme of immunoglobulin followed by rituximab therapy.
    Sánchez-Ramón S; Ravell JC; de la Torre I; Montoro M; Rodríguez-Mahou M; Carreño-Pérez L; Fernández-Cruz E; López-Longo FJ
    Rheumatol Int; 2010 Apr; 30(6):817-9. PubMed ID: 19536548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels.
    Göttfried I; Seeber A; Anegg B; Rieger A; Stingl G; Volc-Platzer B
    Eur J Dermatol; 2000; 10(1):29-35. PubMed ID: 10694294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.
    Barbasso Helmers S; Dastmalchi M; Alexanderson H; Nennesmo I; Esbjörnsson M; Lindvall B; Lundberg IE
    Ann Rheum Dis; 2007 Oct; 66(10):1276-83. PubMed ID: 17277004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis.
    Danieli MG; Calcabrini L; Calabrese V; Marchetti A; Logullo F; Gabrielli A
    Autoimmun Rev; 2009 Dec; 9(2):124-7. PubMed ID: 19386287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study.
    Aggarwal R; Schessl J; Charles-Schoeman C; Bata-Csörgő Z; Dimachkie MM; Griger Z; Moiseev S; Oddis CV; Schiopu E; Vencovský J; Beckmann I; Clodi E; Levine T;
    Arthritis Res Ther; 2024 Jan; 26(1):27. PubMed ID: 38233885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multifocal motor neuropathy: a retrospective study of the response to high-dose intravenous immunoglobulin (IVIg) and current perspectives for diagnosis and treatment].
    Léger JM; Viala K; Maisonobe T; Bouche P
    Bull Acad Natl Med; 2007 Oct; 191(7):1395-407; discussion 1407-9. PubMed ID: 18447061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients.
    Cherin P; Piette JC; Wechsler B; Bletry O; Ziza JM; Laraki R; Godeau P; Herson S
    J Rheumatol; 1994 Jun; 21(6):1092-7. PubMed ID: 7932419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients.
    Cherin P; Herson S; Wechsler B; Piette JC; Bletry O; Coutellier A; Ziza JM; Godeau P
    Am J Med; 1991 Aug; 91(2):162-8. PubMed ID: 1714235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients.
    Foreman C; Russo P; Davies N; Hissaria P; Proudman S; Hughes T; Limaye V
    Intern Med J; 2017 Jan; 47(1):112-115. PubMed ID: 28076913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multifocal motor neuropathies with conduction block: long-term follow-up of ten patients treated with IVIg].
    Cros D; Drake K
    Rev Neurol (Paris); 2006 Jun; 162 Spec No 1():3S46-3S50. PubMed ID: 17075525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short and long-term effect of IVIg in demyelinating neuropathy associated with MGUS, experience of a monocentric study.
    Théaudin M; Lozeron P; Lacroix C; Chrétien P; Ducot B; Denier C; Adams D
    Rev Neurol (Paris); 2011 Dec; 167(12):897-904. PubMed ID: 22023823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.